Category - Developments

Developments

R&M features Izotropic in US breast cancer analysis and forecast

Izotropic (CSE:IZO; OTCQB:IZOZF; FSE:1R3) announced its inclusion in a Research and Markets (R&M) report analyzing the US breast cancer screening and diagnostic market. According to Izotropic, the R&M analysis...

January 17, 2025

Developments

Evaxion completes dosing of personalized vaccine for advanced melanoma

Evaxion Biotech (NSADAQ:EVAX) has announced the completion of dosing for 16 patients in a Phase 2 trial of its lead asset, EVX-01, a personalized cancer vaccine under development for advanced melanoma. According to...

January 16, 2025

Developments

Avicanna and Vectura forge scientific and medical affairs collaboration

Avicanna (TSX:AVCN; OTCQX:AVCNF; FSE:ONN) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma to establish a joint committee aimed at enhancing the understanding of medical cannabis...

January 16, 2025

Developments

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

OS Therapies (NYSE-A:OSTX) has announced positive data from its Phase 2b clinical trial of OST-HER2, its targeted immunotherapy candidate, in the rare, pediatric-designated indication of preventing recurrent, fully...

January 15, 2025

Developments

Peer-reviewed journal accepts Spago’s article on trial results for publication

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) announced that its article on the results of the SPANGOPIX-01 clinical trial of pegfosimer manganese (SN132D) for contrast-enhanced MRI of breast cancer has been accepted for...

January 15, 2025

Developments

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Vistagen (NASDAG:VTGN) announced positive results from its exploratory Phase 2a study of PH284, an investigational pherine nasal spray for cancer cachexia— a condition characterized by appetite loss and severe wasting...

January 15, 2025

Developments

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

Firefly Neuroscience (NASDAQ:AIFF) has announced the discovery of a novel biomarker capable of estimating the biological age of a patient’s brain through its FDA-cleared Brain Network Analytics (BNA) technology platform...

January 14, 2025

Developments

ORIC enters into clinical supply agreement with Janssen

ORIC Pharmaceuticals (NASDAQ:ORIC) has announced a supply agreement with Janssen Research & Development to evaluate ORIC-114, a brain penetrant, oral bioavailable, irreversible EGFR/HER2 inhibitor, in combination...

January 14, 2025

Developments

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Adaptive Biotechnologies (NASDAQ:ADPT) and NeoGenomics (NASDAQ:NEO) have announced a multi-year exclusive collaboration aimed at advancing minimal residual disease (MRD) monitoring options for patients with select blood...

January 14, 2025

Developments

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

Closely-held Clear Labs announced the successful completion of a $30 million series D financing round aimed at accelerating the development and adoption of its cutting-edge sequencing solutions. According to Clear Labs...

January 13, 2025

Category - Developments

R&M features Izotropic in US breast cancer analysis and forecast

Evaxion completes dosing of personalized vaccine for advanced melanoma

Avicanna and Vectura forge scientific and medical affairs collaboration

OS Phase 2b trial of immunotherapy candidate achieves primary endpoint with statistical significance

Peer-reviewed journal accepts Spago’s article on trial results for publication

Vistagen reports positive Phase 2a results for nasal spray in cancer cachexia

Firefly’s groundbreaking BNA technology identifies brain age biomarker, potentially advancing early Alzheimer’s screening

ORIC enters into clinical supply agreement with Janssen

Adaptive partners with NeoGenomics to advance blood cancer monitoring

Clear Labs secures $30 million in series D financing to advance sequencing solutions; adds Kevin Keegan to BOD

General

More